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Background: To determine whether early monitoring of the effects of bevacizumab in patients with recurrent
high-grade gliomas, by a Perfusion Computed Tomography (PCT), may be a predictor of the response to treatment
assessed through conventional MRI follow-up.
Methods: Sixteen patients were enrolled in the present study. For each patient, two PCT examinations, before and
after the first dose of bevacizumab, were acquired. Areas of abnormal Cerebral Blood Volume (CBV) were manually
defined on the CBV maps, using co-registered T1- weighted images, acquired before treatment, as a guide to the
tumor location. Different perfusion metrics were derived from the histogram analysis of the normalized CBV (nCBV)
maps; both hyper and hypo-perfused sub-volumes were quantified in the lesion, including tumor necrosis. A two-tailed
Wilcoxon test was used to establish the significance of changes in the different perfusion metrics, observed at baseline
and during treatment. The relationships between changes in perfusion and morphological MRI modifications at first
follow-up were investigated.
Results: Significant reductions in mean and median nCBV were detected throughout the entire patient population,
after only a single dose of bevacizumab. The nCBV histogram modifications indicated the normalization effect of
bevacizumab on the tumor abnormal vasculature. An improvement in hypoxia after a single dose of bevacizumab was
predictive of a greater reduction in T1-weighted contrast-enhanced volumes at first follow-up.
Conclusions: These preliminary results show that a quantification of changes in necrotic intra-tumoral regions could be
proposed as a potential imaging biomarker of tumor response to anti-VEGF therapies.
Keywords: Perfusion CT, Anti-angiogenic therapy, Bevacizumab, Brain tumor, HypoxiaBackground
Despite new treatments, the median survival of Malignant
Gliomas (MGs) remains poor, ranging from 12 to 15 months
for Glioblastoma Multiforme (GBM) and from 2 to 5 years
for anaplastic gliomas. Such a dismal prognosis can mainly
be ascribed to the rapid onset of radio and/or chemo-resist-
ance, as well as to the limited therapeutic options available
for MGs which recur after standard treatment [1-3].* Correspondence: vidiri@ifo.it
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reproduction in any medium, provided the origGlioblastoma Multiforme (GBM) is a highly vascular
brain tumor with an elevated expression of Vascular
Endothelial Growth Factor (VEGF), a protein that pro-
motes endothelial cell proliferation and migration and,
consequently, tumor angiogenesis. Bevacizumab, a
humanized monoclonal antibody that inhibits VEGF,
administered alone or combined with cytotoxic agents,
has shown promising results in terms of outcome of dis-
ease treatment in progressive MGs [4-6].
Standard criteria to determine the response to treat-
ment are based on the evaluation of morphological Mag-
netic Resonance Imaging (MRI), that allows dimensional. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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enhancing components (infiltration component), depicted
on post-contrast T1-weighted and T2-weighted/Fluid–
Attenuated Inversion Recovery (FLAIR) sequences, re-
spectively [7].
Non-morphological techniques, such as Perfusion
Computed Tomography (PCT) or Perfusion MRI [8-12],
diffusion and spectroscopic MRI [13-15] have been pro-
posed as tools that may offer more detailed information
about the outcome of anti-angiogenic therapies. Of all
the diagnostic modalities available, PCT imaging appears
to be an appropriate and powerful not-invasive tech-
nique to measure the hemodynamic properties of tissues,
such as blood volume, vessel leakiness and permeability
[8].
The purpose of the present study was the early moni-
toring of the effects of bevacizumab in patients with a
recurrent high-grade glioma, with a PCT examination
before and after the first dose of the drug. We hypothe-
sized that a quantitative evaluation of the changes in
tumor perfusion during treatment could be predictive of
the response to the anti-angiogenic therapy.
Methods
Patient population and study design
This prospective, single-center, open-label trial was
approved by our Ethic Committee and informed consent
was obtained from each patient before the study. From
June 2009 to May 2011, a total of 25 patients met the
following selection criteria and were prospectively en-
rolled in the study. Patients were eligible for the study if
they had: (i) a pathologically proven high-grade malignant
glioma (anaplastic astrocytoma, anaplastic oligoastrocytoma,
anaplastic oligodendroglioma, or GBM); (ii) undergone
surgery; (iii) a recurrent or progressive disease after
chemo-radiotherapy (after a total dose of 60 Gy, 2 Gy per
fraction, with concurrent and/or sequential Temozolo-
mide); (iv) a Karnofsky performance status (KPS) greater
than 60; and (v) if they were at least 18 years old. Among
25 patients who met the selection criteria, 9 were excluded
from the analyses for inadequate PCT examination
(3 patients), lack of the second PCT exam for a rapidly
deteriorating condition (4 patients) or lost from follow-up
(2 patients).
The final study cohort included 16 patients, 6 female
and 10 male with an average age of 47.6 years (range,
34–67 years). Patient and tumor characteristics are sum-
marized in Table 1. Patients received bevacizumab as a
monotherapy or combined with other therapies, (Table 1).
Patients also received corticosteroids as clinically demanded.
Bevacizumab was administered every 3 weeks with a dose
of 15 mg/Kg, until disease progression, refusal of patient or
intolerable toxicity. The Progression Free Survival (PFS) was
estimated from the beginning of anti-angiogenic therapyto radiologic and/or neurological progression. The overall
survival (OS) was defined from the beginning of anti-angio-
genic therapy to death.
For each patient, a baseline PCT was performed before
the onset of treatment and the first dose of bevacizumab
was administered the same day. The second PCT was
performed immediately before the second dose of beva-
cizumab, with a median interval of 3 weeks (range, 2.8–
3.6 weeks) from the onset of treatment. All patients
underwent a baseline MRI exam within two weeks before
the onset of treatment and a second MRI exam after the
third dose of bevacizumab, with a median interval of
8.7 weeks, (range, 8.5 – 13 weeks) from the start of
treatment.
Conventional MR imaging: acquisition and volume
quantification
MRI was performed in the first 10 patients with a 0.5 T
superconductive system (Gyroscan, Philips Healthcare,
Eindhoven, The Netherlands) and in the remaining 6
patients with a 1.5 T superconductive system (OptimaTM
MR450w, GE Medical System, Waukesha, WI), using a
standard birdcage head-coil and a 16-channel phased
array head-coil, respectively. Because it was recognized
that contrast-enhancement is nonspecific and patients
treated with anti-angiogenic agents may develop tumor
recurrence characterized by an augmented non-enhancing
component [16], both FLAIR and contrast-enhanced T1-
weighted sequences were considered for the response
assessment to treatment [7]. On the 0.5 T system, axial
FLAIR images were obtained with the following para-
meters: TI = 2000 ms, TE/TR=150 ms/6000 ms, slice
thickness= 6 mm; matrix size= 512×512 and voxel size =
0.5 × 0.5 × 6.0 mm3. Contrast-enhanced T1-weighted spin-
echo (SE) images were acquired on multiple planes (axial,
coronal and sagittal) after the administration of Gadopen-
tate Dimeglumine (Gd-DTPA, Magnevist, Bayern Shering
Pharma AG, Berlin, Germany) at 0,2 mmol per kilogram
of body weight (TR/TE=15 ms/355 ms, slice thickness = 6
mm; matrix size = 512× 512 and voxel size = 0.5 × 0.5 × 6.0
mm3). On the 1.5 T system, FLAIR images were obtained
with the following parameters: TI = 2750 ms, TE/TR=144
ms/11000 ms, slice thickness = 4 mm; matrix size = 512×
512 and voxel size = 0.5× 0.5 × 4.0 mm3. Contrast-
enhanced T1-weighted SE sequences were obtained after
the administration of 0.2 mmol/Kg of Gd-DTPA, with TR/
TE=20 ms/460 ms, and the same spatial resolution para-
meters indicated above.
Volumes of signal abnormality on both axial FLAIR
and contrast-enhanced T1-weighted images (VFLAIR and
VT1), pre-treatment and at the first follow-up, were seg-
mented using a semi-automated region growing algo-
rithm with 3D Slicer Software [17]. All defined volumes
of interest (VOIs) excluded resection cavities and special
Table 1 Patient, tumor characteristics and outcome of Bevacizumab
Patient
n°










1 F 65 R P GBM 70 70 FTM Partial No progress
2 M 34 L T AOA 80 90 - Stable 1.3
3 M 67 R F T GBM 90 70 FTM Stable 4.5
4 M 27 R T P AOD 100 80 FTM Stable 5.0
5 M 49 L F AOD 100 70 TMZ Stable 2.1
6 M 41 L F AOA 100 70 TMZ Stable 3.1
7 M 62 L T GBM 100 80 FTM Stable 4.0
8 F 42 L T AA 70 70 FTM Stable 3.0
9 F 41 R T GBM 80 70 TMZ Stable No progress
10 M 50 L T P GBM 80 80 TMZ+ FTM Progression 2.2
11 M 60 L F P GBM 90 90 FTM Progression 1.6
12 M 43 CC GBM 100 80 - Partial 2.9
13 F 48 R T P GBM 70 80 - Progression 2.0
14 F 43 L T P GBM 80 80 FTM Partial No progress
15 F 42 L T AOD 100 80 - Partial No progress
16 M 48 L P AOD 100 80 - Partial 4.0
Abbreviations: Sex: M, male; F, female. Location: R, right; L, left; P, parietal; T, temporal; F, frontal; CC, corpus callosum. Histology: GBM, glioblastoma multiforme;
AOA, anaplastic oligoastrocytoma; AOD, anapalstic oligodendroglioma; AA, anaplastic astrocytoma; KPS, Karnofsky performance status at initial diagnosis and before
treatment with bevacizumab. FTM, fotemustine; TMZ, temozolamide. PFS, progression free survival counted from the onset of treatment with bevacizumab to
radiological and/or neurological progression as months.
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delineations between the two MRI scans.CT perfusion imaging
PCT examinations were performed by using a 128-section
(Brilliance CT 128-slice CT system- Philips Medical
Systems, Eindhoven, Holland) multidetector-row com-
puted tomography scanner. A preliminary un-enhanced
CT scan was obtained to localize the tumor at a slice
thickness of 5 mm. Fifty milliliters of nonionic iodinated
contrast medium (iopamidol-370 mg I/mL, Bracco,
Milan, Italy) was injected at a rate of 5 mL/s through the
antecubital vein. Five seconds after the injection began,
a 60 s cine scan with 2 s interval was acquired at the
chosen slice locations. Eight 5-mm-thick axial sections
were acquired resulting in a total coverage of 4 cm. Par-
ticular attention was paid to investigate the same portion
of brain volume before and during treatment for each
patient, assuring that the head and neck were relaxed
but without rotation in either plane.
The dose per scan was calculated by ImPACT CT Patient
Dosimetry Calculator (v. 0.99×, Medical Devices Agency,
London), resulting in a total effective dose less than 5 mSv.
CT acquired images were sent to a commercially avail-
able workstation (Brain Perfusion, Brilliance Workspace
Portal, v. 2.5.1.15, Philips Medical Solutions, Eindhoven,
Holland) to generate perfusion maps. A neuroradiologist
(blinded to the review process) selected the AnteriorCerebral Artery (ACA) or alternatively the Middle Cere-
bral Artery (MCA) as input artery; a large venous struc-
ture, such as the sagittal sinus was chosen as the input
vein. To avoid partial volume effects the reference vessels
had to be well recognizable, large enough and sufficiently
orthogonal to the scan section. Parametric Cerebral Blood
Volume (CBV) maps were then generated and stored.
Volume of interest definition on the CBV maps
For each patient, pre-treatment contrast-enhanced T1-
weighted images were accurately co-registered with the
two PCT studies, using the rigid body transformation
module of 3D Slicer Software, based on the mutual infor-
mation algorithm. Before delineating the VOI on the
CBV maps, a visual inspection was performed to ensure an
adequate alignment between MR/CT studies. CBV maps
were then overlaid on the co-registered T1-weighted images
that were used to guide the tumor location. An expert radi-
ologist was asked to manually identify the abnormal CBV
areas (necrotic as well as hyper-perfused), on the eight slices
acquired. Taking the contralateral hemisphere as control re-
gion, a visual inspection was performed to verify whether
arterial or venous structures were involuntary included
inside the VOI (an example is illustrated in Figure 1).
Quantitative analysis of the CBV maps
The quantitative analysis of the perfusion maps was
performed using the Matlab code (Release 7.4.0, The
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developed by a medical physicist (blinded to the review
process), with more than 10 years’ experience in data
analysis, to perform calculations based on voxel-by-voxel
information. The CBV maps, generated by the commer-
cial workstation, were loaded in the Matlab workspace
and divided by the CBV mean inside a healthy region of
about 1 cm2, in the hemisphere contralateral with re-
spect to the lesion, to obtain the normalized CBV
(nCBV) maps. For each patient, the same region was
chosen to derive the nCBV maps at baseline and after
the first dose of bevacizumab. Assuming a fixed nCBV
bin size of 0.5, the distribution of the voxel counts as aFigure 1 Volume of Interest delineation. Axial CT slice illustrating a secti
co-registered to the CT slice (b); co-registered transverse contrast-enhanced
region of abnormal perfusion on the CBV map (in blu) (d).function of the bin locations (differential histogram) was
recorded and displayed for each PCT.
The VOIs with abnormal CBV delineated by 3D Slicer
Software (Figure 1) were loaded in the Matlab workspace
and used to quantify, within them, the distribution of
nCBV values (nCBV histogram). Specific hypo- and
hyper-perfused sub-volumes were calculated, as the ab-
solute voxel count within the VOIs in which nCBV
values were less or greater than fixed thresholds, respect-
ively. Three hypo-perfused sub-volumes were determined
as the volumes with nCBV less or equal to 1.0, 0.5 and 0
(tumor necrosis), defined as V≤ 1.0, V≤ 0.5 and V= 0.
Analogously, five hyper-perfused sub-volumes wereon of the tumor (a); transverse contrast-enhanced T1-weighted image
T1-weighted image overlaid on the CBV map (c); the user-defined
Table 2 Results of Wilcoxon test, to establish if early
changes of perfusion metrics are significant
Summary statistics for nCBV Mean Median SD
p value 0.0006 0.0042 0.0076
Hypo-perfused sub-volumes V≤ 1.0 V≤ 0.5 V= 0
p value 0.43 0.78 0.90
Hyper-perfused sub-volumes V≥ 1.5 V≥ 2.0 V≥ 2.5 V≥ 3.0 V≥ 3.5
p value 0.0001 0.0001 <0.0001 <0.0001 <0.0001
Abbreviations: nCBV= normalized cerebral blood volume; SD= standard
deviation; V≤ 1.0= is the total number of voxels, within the volume of interest,
in which nCBV is≤ 1.0 (analogously for V≤ 0.5 and V= 0); V≥ 1.5= is the total
number of voxels, within the volume of interest, in which nCBV is≥ 1.5
(analogously for V≥ 2.0-V≥ 3.5).
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1.5, 2.0, 2.5, 3.0, and 3.5 defined as V≥ 1.5-V≥ 3.5.
Statistics
A two-tailed Wilcoxon test for paired samples was used
to establish if changes of the same variable, observed at
different time points, were significant. The relationships
between modifications based on perfusion metrics and
morphological MRI changes/PFS/OS were investigated
using the Pearson correlation test. Unless otherwise indi-
cated, summary statistics were reported as median and
standard deviations. A two-sided p-value< 0.05 was con-
sidered to indicate statistical significance. The MedCalc
software (Version 9, Mariakerke, Belgium) was used for
the statistical analyses.
Results
According to RANO criteria, five patients showed a par-
tial response, eight were described as clinically stable and
three had a progression of disease (Table 1). From June
2009 up to now, all but 4 had a progression and died of
progressive disease. The median PFS for the remaining
12 patients was 3.0 months (range, 1.3–5.0 months), with
a median OS of 4.8 months (range, 1.6–14.8 months).
T1 post-contrast and flair volumetric analysis
Before treatment, the volumes VT1 and VFLAIR were
27.4±13.4 cm3 and 111.7±53.0 cm3, respectively and at the
first follow-up, were 16.1±33.8 cm3 and 112.8±80.9.0 cm3,
respectively. As percentages, VT1 and VFLAIR at the first
follow-up relative to the initial volumes, were 59.2 ± 88.3%
and 97.1 ± 70.2%, respectively, showing a decrease in VT1
and a stability of VFLAIR. Considering all patients, no stat-
istical significance appeared in either of the sequences,
both in absolute units and percentages.
Analysis of changes in CBV
The nCBV mean, median and standard deviation (SD)
within the VOI showed a strongly significant decrease
during treatment, throughout the entire patient popula-
tion (Table 2): the baseline values were 2.3, 2.5 and 1.6,
respectively, while after the first dose of bevacizumab
they were 1.2, 1.5 and 1.0, respectively. Changes in mean
and median nCBV reflect an appreciable tumor vascula-
ture normalization because of the effect of the anti-
angiogenic agent.
All the hyper-perfused sub-volumes (V≥ 1.5–V≥ 3.5)
showed an even more significant decrease during treat-
ment, with p values ≤ 0.0001. On the contrary, the
changes of the hypo-perfused sub-volumes, including the
necrotic region (V=0), were not significant (Table 2).
The nCBV mean values inside the VOI, before treat-
ment and after a single dose of bevacizumab, are dis-
played for each patient in Figure 2. Baseline values havebeen expressly sorted in ascending order to understand
whether the normalization effect of bevacizumab could
somehow depend on the perfusion level of the lesion be-
fore treatment.
Correlations between early CBV changes and MRI
response/PFS/OS
Only the percentage change of the necrotic sub-volume
(V=0), relative to the pre-treatment value, showed a signifi-
cant relationship with the percentage VT1 modification at
the first follow-up (correlation coefficient r=0.829, 95%
Confidence Interval = 0.551–0.942, p-value= 0.0001). None
of the variations of the other parameters, including nCBV
mean, median, SD or any of the hyper-perfused sub-
volumes, showed significant relationships with VT1 and
VFLAIR changes.
A tendency of correlation was found between the per-
centage change of V=0 and PFS (p=0.09), while no correl-
ation emerged between the observed perfusion changes
and OS.
In the subgroup of patients stable or with a progres-
sion of disease (11 in total), the mean changes of V≤ 1.0,
V≤ 0.5, V= 0 were 61.5%, 68% and 4.3%, respectively; while
in the subgroup of patients with partial response (5 in
total), the changes were 10.4%, -9.4% and -59.1%, re-
spectively. Analogously, for patients stable or in progres-
sion, the variations of V≥ 1.5, V≥ 2.0, V≥ 2.5, V≥ 3.0, V≥ 3.5
were −44.1%, -61.8%, -51.2%, -51,7%, -60.2%, respectively,
while for partially responding patients, they were −53.1%,
-65.2%, -70.%, -75.5%, -81.4%, respectively.
Representative cases
Case 1
In Figure 3 the case of a 43-year-old man affected by
GBM in the corpus callosum is illustrated (Patient 12),
who received bevacizumab as single therapy. Comparing
the CBV maps, acquired before and during treatment, a
decreased blood volume is noticeable in the region of
interest; this behavior is more exhaustively illustrated by
a comparison between the nCBV histograms within the
Figure 2 Normalized cerebral blood volume for each patient. Mean values of the normalized cerebral blood volume (nCBV), before treatment
and after the first dose of bevacizumab, for each patient.
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tions of the nCBV values indicate a reduction in both
hyper-/hypo-perfused sub-volumes, in accordance with a
decreased hyperintensity, shown by the post-constrast
T1-weighted and FLAIR (data not shown) images,
acquired 7 weeks after the onset of treatment. The pa-
tient was classified as partially responding, in accordance
with RANO criteria. Approximately 1 month after the
MRI scan, the patient showed a rapid deterioration of
the clinical condition due to meningitis and died ap-
proximately 1 month later.Case 2
Figure 4 shows a 50-year-old man affected by a GBM in
the left temporal region (Patient 10), who received beva-
cizumab with concurrent temozolamide and fotemustine.
The CBV map, acquired after the first dose of bevacizu-
mab, shows rapid growth of the necrotic area, that has
completely replaced the hypervascularized region docu-
mented by the baseline CBV map. This is displayed in
more detail by the nCBV histograms, showing a signifi-
cant decrease in the hyper-perfused regions but, contem-
porary, a marked increase in the hypo-perfused sub-
volumes inside the VOI, in particular V=0 increases by
425% with respect to the baseline value. These abnormalCBV areas seem to be predictive of the subsequent
changes in contrast enhancement, as documented by the
post-Gd T1-weighted images acquired before (Figure 4c)
and at 10 weeks from the onset of treatment (Figure 4d).
The patient was defined as progressive and died two
months after the MRI scan.Discussion
In the present study, we aimed at investigating whether
PCT may be used to obtain early non-invasive imaging
biomarkers of the response to anti-angiogenic therapy, in
patients affected by recurrent high-grade gliomas. There
is strong interest in validating biomarkers which could
prove to be predictive of response to treatment, to better
stratify the patients most likely to benefit from these
therapies.
Our results indicate that large reductions in mean and
median nCBV can be detected throughout the entire pa-
tient population, after only a single dose of bevacizumab.
From the analysis of each patient (Figure 2), it is notice-
able that mean nCBV after bevacizumab has a tendency
to approach the value of 1, that represents the mean
nCBV of the normal appearing brain tissue. The SD also
significantly decreased after the first cycle of bevacizu-
mab, indicating a narrower distribution of nCBV values
Figure 3 Representative case 1. A 43-year-old man (Patient 12) affected by a glioblastoma multiforme in the corpus callosum. Cerebral Blood
Volume (CBV) map illustrating a section of the lesion before treatment (a); co-registered transverse post-Gd T1-weighted image showing an area
of increased contrast enhancement, before treatment (b); CBV map acquired during treatment indicates a decreased blood volume in the region
of interest (c); transverse post-Gd T1-weighted image, acquired 7 weeks after the onset of treatment, shows a decrease in contrast enhancement
(d). Differential histogram of normalized CBV (nCBV) values inside the volume of interest, before treatment (e) and after a single dose of
bevacizumab (f), showing a decrease in both hyper/hypo-perfused subvolumes.
Figure 4 Representative case 2. A 50-year-old man affected by a glioblastoma multiforme in the left temporal region (Patient 10): Cerebral
Blood Volume (CBV) map illustrating a section of the lesion before treatment (a); co-registered transverse post-Gd T1-weighted image showing
the area of increased contrast enhancement, before treatment (b); normalized CBV (nCBV) map showing the modification of the blood volume
after a single dose of bevacizumab (c); co-registered transverse post-Gd T1-weighted image acquired at the first follow-up, showing an
augmented area of contrast enhancement and necrosis (d). Differential nCBV histogram inside the volume of interest, before treatment (e) and
after a single dose of bevacizumab (f), showing a decrease in the hyper-perfused regions but an increase in the hypo-perfused sub-volumes.
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tumor vascular heterogeneity as visually documented by
perfusion maps acquired during treatment. However, for
an initial mean nCBV greater than 2.5, this normalization
effect seems to be less efficient, suggesting that a high
perfusion at baseline may correspond to reduced activity
of the anti-angiogenic agent, even if this trend should be
supported by further investigation on a larger patient
population.
Among all different perfusion metrics derived from
CBV maps, the most significant changes were found for
the hyper-perfused sub-volumes (particularly p< 0.0001
for a cutoff of nCBV greater than 2.5, Table 2). A similar
method of quantitative analysis was performed by
Sawlani et al. [11], who calculated size, mean relative
CBV, mean leakage coefficient and hyperperfusion vol-
ume (HPV), in 16 patients with recurrent GBM receiving
bevacizumab, both at baseline and at the first follow-up
(6 weeks). The HPV, with a cutoff of relative CBV greater
than 1, proved to be the metric with a significantly better
correlation with the time to progression, thus it was pro-
posed as a valid measure of response to anti-angiogenic
chemotherapy. A direct comparison between the two stud-
ies is not possible, primarily because of the different timing
of the perfusion studies (patients of our study underwent
a perfusion exam at a median interval of 3 weeks from
the onset of treatment vs 6 weeks) and, secondly, because
of the different perfusion imaging modality (MR vesus
CT). However, in accordance with Sawlani et al. [11], we
observed that partially responding patients exhibited
greater percentage changes in hyper-perfused sub-volumes
than patients clinically stable or with disease progression
(V≥ 2.5, V≥ 3.0 and V≥ 3.5 were -70.%, -75.5%, –81.4% versus
-51.2%, -51,7%, -60.2%, respectively for the two groups of
patients).
In our opinion, the most interesting finding of the
present investigation was derived from monitoring the
less-oxygenated regions in the tumor. The early modifi-
cations in this region are the only ones which correlate
with percentage changes in T1-weighted contrast-
enhanced volumes at first follow-up (p= 0.0001).
The important role of intra-tumor hypoxia in anti-
VEGF therapies has emerged from a few recent reports
[15,18,19]. Masunaga et al. [18] evaluated the influence
of bevacizumab on intra-tumor oxygenation status in
mice, distinguishing between acute and chronic hypoxia
resulting from limited perfusion and limited oxygen dif-
fusion, respectively. The authors concluded that bevaci-
zumab preferentially oxygenated the acutely Hypoxic
Fraction (HF) rather than the chronically HF in the
tumor. So, the remaining HF after anti-angiogenic treat-
ment should preferentially be composed of a chronic
hypoxia-rich cell population, whose control was found to
have a significant impact on the local control of thetumor. Thus, the evidence of increased necrotic areas in-
side the lesion during therapy (as documented in Figure 4
for a patient described as clinically in progression of dis-
ease) should represent an early indication of treatment
failure, due to the lack of local tumor control.
Hattingen et al. [15] investigated whether bevacizumab
altered oxygen and energy metabolism and showed anti-
tumoral effects in recurrent GBM, by using 31P and 1H
MRSI and diffusion MRI, at baseline and after the first
cycle of bevacizumab. They also indirectly evaluated
blood oxygenation by a quantitative mapping of T2 and
T2’ relaxation times, reporting that bevacizumab induces
relative tumor hypoxia (T2’ decrease). However, the
authors stated that this long-term hypoxia does not seem
to promote more aggressive tumor growth, because no
association was found between the T2’reduction and a
shorter OS duration.
The promising but yet controversial effect of bevacizu-
mab have been recently reported by Keunen et al. [20],
whose data strongly suggest that vascular remodeling
induced by anti- VEGF treatment may lead to a more
hypoxic tumor microenvironment and, consequently, to
enhanced tumor cell invasion into the normal brain.
Studies combining imaging with molecular biomarkers
will probably make a substantial contribution to a better
understanding of the complex cellular mechanisms by
which bevacizumab temporarily corrects the abnormal
vasculature of tumors [9,19]. Anti-hypoxia inducible
factor-1α (HIF−1α) have recently been shown to have a
link with perfusion imaging. Yopp et al. [19] analyzed a
group of patients with primary liver cancer treated with
floxuridine and bevacizumab and found that reductions
in tumor perfusion were greater in tumors expressing
HIF−1α.
To our knowledge, this is the first investigation using
PCT to evaluate the response to anti-angiogenic therap-
ies in patients with brain tumors. Data on CT perfusion,
as a biomarker in oncology, for the response to therapy
are to date insufficient [8], in spite of the advantage of
PCT for providing absolute perfusion data, thanks to the
linear relationship between CT enhancement and con-
trast agent concentration compared to MR perfusion. Al-
though the feasibility of PCT for routine diagnosis is
mainly limited for the use of ionizing radiation, selecting
a low kVp X-ray beam and optimizing the scanning
protocol, i.e. image interval and scanning duration, it is
possible to reduce the radiation dose to the patient to ac-
ceptable levels of total effective dose.
There are some limits to our study. The 4-cm coverage
of PCT in cranio-caudal direction precluded us from in-
vestigating, in some patients, the entire tumor volume
and, in these cases, only the central portion of the lesion
was examined. Furthermore, two different MR systems
were used to evaluate the VT1 and VFLAIR changes, which
Vidiri et al. Journal of Experimental & Clinical Cancer Research 2012, 31:33 Page 9 of 10
http://www.jeccr.com/content/31/1/33represents a potential bias of the study because the mag-
netic field intensity affects the signal to noise ratio and
may have an impact on the dimensional measurement of
the VT1 and VFLAIR. However, this bias is attenuated by
the fact that only relative measurements (volume varia-
tions expressed as percentages) were correlated with the
different perfusion metrics, and the same MR system was
used, before and at first follow-up, for the each patient.
Due to the low statistical power of the analyzed patient
group, a few correlations were found between the observed
perfusion changes and clinical endpoints, i.e. PFS and OS
(only a tendency of correlation emerged between changes
in V=0 and PFS). Additional studies are warranted, includ-
ing a larger number of patients, to better investigate the
relationships between the proposed perfusion metrics and
clinical outcomes.
Finally, laborious data processing is needed for each
patient to accurately co-register the acquired MR/CT
exams, delineate all VOIs and obtain, by home-made
software, a quantification of hyper-/hypo-perfused sub-
volumes in the lesion. The proposed method of analysis
not being included in routine measurements, our results
are not easily reproducible by other research groups for
further validation.
Conclusions
In summary, our results underline the utility to quantify
the variations of the entire distribution of CBV values in
the tumor, by the use of metrics based on histogram ana-
lysis. We found that an improvement in hypoxia after a
single dose of bevacizumab was a predictor of a greater
reduction in T1-weighted contrast-enhanced volumes at
first follow-up. We propose that a quantification of
changes in necrotic intratumoral regions may be consid-
ered as an alternative imaging biomarker of the tumor
response to anti-VEGF therapies.
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